These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 26227776)

  • 1. Radiolabelling and positron emission tomography of PT70, a time-dependent inhibitor of InhA, the Mycobacterium tuberculosis enoyl-ACP reductase.
    Wang H; Liu L; Lu Y; Pan P; Hooker JM; Fowler JS; Tonge PJ
    Bioorg Med Chem Lett; 2015 Nov; 25(21):4782-4786. PubMed ID: 26227776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A slow, tight binding inhibitor of InhA, the enoyl-acyl carrier protein reductase from Mycobacterium tuberculosis.
    Luckner SR; Liu N; am Ende CW; Tonge PJ; Kisker C
    J Biol Chem; 2010 May; 285(19):14330-7. PubMed ID: 20200152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Time-dependent diaryl ether inhibitors of InhA: structure-activity relationship studies of enzyme inhibition, antibacterial activity, and in vivo efficacy.
    Pan P; Knudson SE; Bommineni GR; Li HJ; Lai CT; Liu N; Garcia-Diaz M; Simmerling C; Patil SS; Slayden RA; Tonge PJ
    ChemMedChem; 2014 Apr; 9(4):776-91. PubMed ID: 24616444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent Advances and Structural Features of Enoyl-ACP Reductase Inhibitors of Mycobacterium tuberculosis.
    Inturi B; Pujar GV; Purohit MN
    Arch Pharm (Weinheim); 2016 Nov; 349(11):817-826. PubMed ID: 27775177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, chemical synthesis of 3-(9H-fluoren-9-yl)pyrrolidine-2,5-dione derivatives and biological activity against enoyl-ACP reductase (InhA) and Mycobacterium tuberculosis.
    Matviiuk T; Rodriguez F; Saffon N; Mallet-Ladeira S; Gorichko M; de Jesus Lopes Ribeiro AL; Pasca MR; Lherbet C; Voitenko Z; Baltas M
    Eur J Med Chem; 2013; 70():37-48. PubMed ID: 24140915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of 2-(4-oxoquinazolin-3(4H)-yl)acetamide derivatives as novel enoyl-acyl carrier protein reductase (InhA) inhibitors for the treatment of tuberculosis.
    Pedgaonkar GS; Sridevi JP; Jeankumar VU; Saxena S; Devi PB; Renuka J; Yogeeswari P; Sriram D
    Eur J Med Chem; 2014 Oct; 86():613-27. PubMed ID: 25218910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemical synthesis, biological evaluation and structure-activity relationship analysis of azaisoindolinones, a novel class of direct enoyl-ACP reductase inhibitors as potential antimycobacterial agents.
    Deraeve C; Dorobantu IM; Rebbah F; Le Quéméner F; Constant P; Quémard A; Bernardes-Génisson V; Bernadou J; Pratviel G
    Bioorg Med Chem; 2011 Nov; 19(21):6225-32. PubMed ID: 21975068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First triclosan-based macrocyclic inhibitors of InhA enzyme.
    Rodriguez F; Saffon N; Sammartino JC; Degiacomi G; Pasca MR; Lherbet C
    Bioorg Chem; 2020 Jan; 95():103498. PubMed ID: 31855823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and synthesis of thiourea-based derivatives as Mycobacterium tuberculosis growth and enoyl acyl carrier protein reductase (InhA) inhibitors.
    Doğan ŞD; Gündüz MG; Doğan H; Krishna VS; Lherbet C; Sriram D
    Eur J Med Chem; 2020 Aug; 199():112402. PubMed ID: 32417538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors.
    am Ende CW; Knudson SE; Liu N; Childs J; Sullivan TJ; Boyne M; Xu H; Gegina Y; Knudson DL; Johnson F; Peloquin CA; Slayden RA; Tonge PJ
    Bioorg Med Chem Lett; 2008 May; 18(10):3029-33. PubMed ID: 18457948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Formulation studies of InhA inhibitors and combination therapy to improve efficacy against Mycobacterium tuberculosis.
    Knudson SE; Cummings JE; Bommineni GR; Pan P; Tonge PJ; Slayden RA
    Tuberculosis (Edinb); 2016 Dec; 101():8-14. PubMed ID: 27865404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, molecular docking and 3D-QSAR studies of potent inhibitors of enoyl-acyl carrier protein reductase as potential antimycobacterial agents.
    More UA; Joshi SD; Aminabhavi TM; Gadad AK; Nadagouda MN; Kulkarni VH
    Eur J Med Chem; 2014 Jan; 71():199-218. PubMed ID: 24292339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of novel InhA reductase inhibitors: application of pharmacophore- and shape-based screening approach.
    Kumar UC; Bvs SK; Mahmood S; D S; Kumar-Sahu P; Pulakanam S; Ballell L; Alvarez-Gomez D; Malik S; Jarp S
    Future Med Chem; 2013 Mar; 5(3):249-59. PubMed ID: 23464516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of gallic acid formazans as novel enoyl acyl carrier protein reductase inhibitors for the treatment of tuberculosis.
    Saharan VD; Mahajan SS
    Bioorg Med Chem Lett; 2017 Feb; 27(4):808-815. PubMed ID: 28117201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of the Mycobacterium tuberculosis enoyl acyl carrier protein reductase InhA by arylamides.
    He X; Alian A; Ortiz de Montellano PR
    Bioorg Med Chem; 2007 Nov; 15(21):6649-58. PubMed ID: 17723305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biological evaluation of potent triclosan-derived inhibitors of the enoyl-acyl carrier protein reductase InhA in drug-sensitive and drug-resistant strains of Mycobacterium tuberculosis.
    Stec J; Vilchèze C; Lun S; Perryman AL; Wang X; Freundlich JS; Bishai W; Jacobs WR; Kozikowski AP
    ChemMedChem; 2014 Nov; 9(11):2528-37. PubMed ID: 25165007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of hydrazone containing thiadiazoles as Mycobacterium tuberculosis growth and enoyl acyl carrier protein reductase (InhA) inhibitors.
    Doğan H; Doğan ŞD; Gündüz MG; Krishna VS; Lherbet C; Sriram D; Şahin O; Sarıpınar E
    Eur J Med Chem; 2020 Feb; 188():112035. PubMed ID: 31951850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacophore mapping, molecular docking, chemical synthesis of some novel pyrrolyl benzamide derivatives and evaluation of their inhibitory activity against enoyl-ACP reductase (InhA) and Mycobacterium tuberculosis.
    Joshi SD; Dixit SR; Basha J; Kulkarni VH; Aminabhavi TM; Nadagouda MN; Lherbet C
    Bioorg Chem; 2018 Dec; 81():440-453. PubMed ID: 30223149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aqueous Molecular Dynamics Simulations of the M. tuberculosis Enoyl-ACP Reductase-NADH System and Its Complex with a Substrate Mimic or Diphenyl Ethers Inhibitors.
    da Silva Lima CH; de Alencastro RB; Kaiser CR; de Souza MV; Rodrigues CR; Albuquerque MG
    Int J Mol Sci; 2015 Oct; 16(10):23695-722. PubMed ID: 26457706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of benzo[d]oxazol-2(3H)-ones derivatives as novel inhibitors of Mycobacterium tuberculosis InhA.
    Pedgaonkar GS; Sridevi JP; Jeankumar VU; Saxena S; Devi PB; Renuka J; Yogeeswari P; Sriram D
    Bioorg Med Chem; 2014 Nov; 22(21):6134-45. PubMed ID: 25282650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.